| I. General Information | OMB Approved \# 0938-0944 (Expires: 8/31/2025) |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1. Contract Number: | 4. Contract Yr: | 2024 | 7. Plan Name: | 10. VBID-D: | N | 12. PD Region: |  | 15. PMM: | N |
| 2. Plan ID: | 5. Org. Name: |  | 8. Plan Type: |  |  | 13. PD Benefit Type: |  | 16. SSM: | N/A |
| 3. Segment ID: | 6. SNP: |  | 9. Enrollee Type: | 11. ESRD-SNP: | N | 14. SNP Type: | N/A |  |  |

II. Base Period Background Information

III. Part D Claims Experience

14. Net PMPM on Supplemental Drugs

| VI. PMPM Income Statement Summary |
| :--- |
|  (m) <br> 1. Premium Revenue $\$ 0.00$ <br> 2. LIS Reimb. $\$ 0.00$ <br> 3. Fed Reins. $\$ 0.00$ <br> 4. Allocated Buy-Down*  <br> 5. Total Revenue  <br> 6. Pharmacy Claims $\$ 0.00$ <br> 7. Non-Benefit Expenses $\$ 0.00$ <br> 8. Total Expenses $\$ 0.00$ <br> 9. Gain/(Loss) Including Buy-Down $\$ 0.00$ |

*MA rebate dollars to buy-down Part D premium (not true revenue)

| Total Non-LI Brand Discount Amount |  |
| :--- | :--- |

PRA Disclosure Statement According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0944. The time required to complete this information collection is estimated to average 30 hours per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

| 1. Contract Number: | 4. Contract Yr: | 2024 | 7. Plan Name: | 10. VBID-D: | N | 12. PD Region: |  | 15. PMM: | N |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2. Plan ID: | 5. Org. Name: |  | 8. Plan Type: |  |  | 13. PD Benefit Type: |  |  |  |
| 3. Segment ID: | 6. SNP: |  | 9. Enrollee Type: | 11. ESRD-SNP: | N | 14. SNP Type: | N/A |  |  |


III. Cost for Covered Part D Drugs

| I. Retail Generic |
| :--- |
| 1. Retail Prefrred Brand |
| 3. Retail Non-Preferred Brand |
| 4. Retail Specialty |
| 5. Mail Order Generic |
| 6. Mair Ordel Preferred Brand |
| 7. Mail Order Non-Preferred Brand |
| 8. Mail Order Specialty |
| 9. Total Retail |
| 10. Total Mail Order |
| 11. Total Generic |
| 12. Total Brand (Preferred and Non-Preferred) |
| 13. Total Specialty |
| 14. Total |


| (e) | (f) | (g) | (h) | (i) |
| :---: | :---: | :---: | :---: | :---: |
| Components of Unit Cost Change |  |  |  |  |
| Inflation Trend | Discount Change | Formulary Change | Other Change | Tot. Un Cost C |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  | 0. |
|  |  |  |  | 0 |
|  |  |  |  | 0. |
|  |  |  |  | 0. |


| V. PMPM Non-Benefit Expenses |
| :--- |
|  <br> 1. Sales and Marketing <br> 2. Direct Administration <br> 3. Indirect Administration <br> 4. Net Cost of Private Reinsurance <br>  <br> 5. Total Non-Benefit Expenses |

VI. Percentage of Revenue

|  | (j) |
| :--- | ---: |
| 1. Claims (Allowable Cost Target): | at 0.000 |
| 2. Non-Benefit Expenses | $\$ 0.00$ |
| 3. Gain/(Loss): | $\$ 0.00$ |
| 4. Total Basic Bid | $\$ 0.00$ |
| 5. Percentage of Revenue | $\$ 0.00$ |
| a. Claims (Allowable Cost Target): |  |
| b. Non-Benefit Expenses | $0.0 \%$ |
| c. Gain/(Loss): | $0.0 \%$ |


| 1. Contract Number: | 4. Contract Yr: | 2024 | 7. Plan Name: | 10. VBID-D: N | 12. PD Region: |  | 15. PMM: | N |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2. Plan ID: | 5. Org. Name: |  | 8. Plan Type: |  | 13. PD Benefit Type: |  |  |  |
| 3. Segment ID: | 6. SNP: |  | 9. Enrollee Type: | 11. ESRD-SNP: N | 14. SNP Type: | N/A |  |  |

## II. Projection Data

$$
\begin{array}{lll}
\text { a } \\
\hline \text { 1. Projected Member Months: } & 0 & \text { 2. Projected Avg Risk Score: } \square \\
\hline
\end{array}
$$

3. Projected LIS Member Months: 4. Projected non-LIS Member Months:
III. Part D Covered Drug Claims

IV. Non-Benefit Expenses and Gain/(Loss)

| 1. | Basic Non-Benefit Expenses | $\$ 0.00$ |
| :--- | :--- | :--- |
| 2. | Supplemental Non-Benefit Expenses | $\$ 0.00$ |
| 3. | Total Non-Benefit Expenses | $\$ 0.00$ |
| 4. | Basic Gain/(Loss) | $\$ 0.00$ |
| 5. | Supplemental Gain/(Loss) | $\$ 0.00$ |
| 6. | Total Gain/(Loss) |  |

V. Defined Standard Coverage Bid Development

|  | (i) | (j) |
| :---: | :---: | :---: |
|  | At 0.000 | At 1.00 |
| 1. Claims (Allowable Cost Target): | \$0.00 | \$0.00 |
| 2. Non-Benefit Expenses | \$0.00 | \$0.00 |
| 3. Gain/(Loss): | \$0.00 | \$0.00 |
| 4. Total Basic Bid | \$0.00 | \$0.00 |
| 5. Federal Reinsurance: | \$0.00 | \$0.00 |

WORKSHEET 4 - Rx STANDARD COVERAGE WITH ACTUARIALLY EQUIVALENT COST SHARING
Page 4 of 8

II. Projection Data


|  | At 0.000 | At 1.00 |
| :---: | :---: | :---: |
| 1. Claims (Allowable Cost Target) | \$0.00 | \$0.00 |
| 2. Non-Benefit Expenses | \$0.00 | \$0.00 |
| 3. Gain/(Loss): | \$0.00 | \$0.00 |
| 4. Total Basic Bid | \$0.00 | \$0.00 |
| 5. Federal Reinsurance | \$0.00 | \$0.00 |
| 6. LIS | \$0.00 |  |


| V. Std. Cov. Bid Development with Actuarially Equivalent C. S. |
| :--- |
|  At 0.000 At 1.00 <br> 1. Claims (Allowable Cost Target) $\$ 0.00$ $\$ 0.00$ <br> 2. Non-Benefit Expenses $\$ 0.00$ $\$ 0.00$ <br> 3. Gain/(Loss): $\$ 0.00$ $\$ 0.00$ <br> 4. Total Basic Bid $\$ 0.00$ $\$ 0.00$ <br> 5. Federal Reinsurance $\$ 0.00$ $\$ 0.00$ <br> 6. LIS  M |

IV: Development of Bid Components and Tests for Actuarial Equivalence

|  | (e) | (g) | (i) | (I) |
| :---: | :---: | :---: | :---: | :---: |
| 1. Total Members |  |  |  | 0 |
| 2. Member Months |  |  |  | 0 |
|  | Amounts below | Amounts in | Amounts above | Row |
|  | Initial Coverage Limit | Gap | Catastrophic Threshold | Subtotal |
|  | <\$4,660 |  |  |  |
| Allowed PMPM |  |  |  |  |
| 3. Standard | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| 4. Standard with Act. Equiv. Cost Sharing | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| 5. Value of Deductible | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| Allowed Subject to Coins. |  |  |  |  |
| 6. Standard | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| 7. Standard with Act. Equiv. Sharing | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| Coins. \% |  |  |  |  |
| 8. Standard | 25.0\% A | 0.0\% | 0.0\% C | 0.0\% |
| 9. Standard with Act. Equiv. Sharing | 0.0\% B | 0.0\% | 0.0\% D | 0.0\% |
| Coins PMPM |  |  |  |  |
| 10. Standard | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| 11. Standard with Act. Equiv. Sharing | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| Net Cost of Benefit |  |  |  |  |
| 12. Standard | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| 13. Standard with Act. Equiv. Sharing | \$0.00 | \$0.00 | \$0.00 | \$0.00 |
| Rebates |  |  | For Reinsurance | Inc Reins. |
| 14. Standard |  |  | \$0.00 | \$0.00 |
| 15. Standard with Act. Equiv. Sharing |  |  | \$0.00 |  |
| Test for Actuarial Equivalence |  |  |  |  |
|  |  |  |  |  |
| 16. $\mathrm{A}=\mathrm{B}$ | No |  |  |  |
| 17. C=D | No |  |  |  |
| 18. Coverage in the Gap | No |  |  |  |
| 19. Insulin | Yes |  |  |  |


| 1. Contract Number | 4. Contract Yr: | 2024 | 7. Plan Name: | 10. VBID-D: | N | 12. PD Region: |  | 15. PMM: N |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2. Plan ID: | 5. Org. Name: |  | 8. Plan Type: |  |  | 13. PD Benefit Type: |  |  |
| 3. Segment ID: | 6. SNP: |  | 9. Enrollee Type: | 11. ESRD-SNP: | N | 14. SNP Type: | N/A |  |

## II. Projection Data

1. Projected Member months
2. Projected Avg Risk Score
0.000
V. Development of Actuarial Equivalence Test

|  | At 0.000 | At 1.00 |
| :--- | ---: | ---: |
| 1. Part D Covered Drugs | $\$ 0.00$ | D |
| 2. Non-Benefit Expenses | $\$ 0.00$ |  |
| 3. Gain/(Loss) | $\$ 0.00$ | $\$ 0.00$ |
| 4. Federal Reinsurance | $\$ 0.00$ |  |
| 5. Total Part D Covered | $\$ 0.00$ | $\$ 0.00$ |
| 6. Non-Part D Covered Drugs | $\$ 0.00$ | $\$$ |
| 7. Total Plan Coverage | $\$ 0.00$ |  |
| 8. Total Basic Bid | $\$ 0.00$ |  |
| 9. LIS | $\$ 0.00$ | $\$ 0.00$ |

IV. Development of Bid Components


## 1. Insulins <br> 1. Insulins 2. Total Coverage $>=$ Std Coverage (B>A) <br> 3. Unsubsidized value $>=$ Unsub Value for $\operatorname{Std} \operatorname{Covg}(1=y$ es and $D>=C)$ <br> 4. Average Cost at Initial Covg Limit >=Std ( $G>=F$ ) <br> 5. Average Cost at initial Covg Li <br> 6. Average Catastrophic cost sharing <=Std ( $1<=\mathrm{H}$ ) <br> 7. Coverage in the Gap ( $K<=J$ )

## vill. Development of Induced Utilization Adjustment

VIII. Development of Induced Utilization Adjustment

|  | At $\mathbf{0 . 0 0 0}$ | At 1.00 |
| :--- | ---: | ---: |
| 1. Claims for Standard | $\$ 0.00$ | $\$ 0.00$ |
| 2. Impact of Alternative Utilization on Standard |  | $\$ 0.00$ |
| 3. Allowable Cost Target for Alternative | $\$ 0.00$ | $\$ 0.00$ |
| 4. Induced Utilization Adjustment |  | 0.000 |

4. Induced Utilization Adjustment
Yes
Yes
Yes
Yes
Yes
Yes
Yes
VII. Development of Supplemental Premium:

| 1. Part D Covered Drugs | At 0.000 |
| :--- | :---: |
| 2. . on Part D Covered Drugs | $\$ 0.00$ |
| 3. Less Basic Covered | $\$ 0.00$ |
| 4. Supplemental Coverage | $\$ 0.00$ |
| 5. Reduction in Reinsurance | $\$ 0.00$ |
| 6. Additional Non-Benefit Expenses | $\$ 0.00$ |
| 7. Additional Gain/(Loss) | $\$ 0.00$ |
| 8. Supplemental Premium | $\$ 0.00$ |



| 1. Contract Number: | 4. Contract Yr: | 2024 | 7. Plan Name: | 10. VBID-D: | N | 12. PD Region: |  | 15. PMM: | $N$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2. Plan ID: | 5. Org. Name: |  | 8. Plan Type: |  |  | 13. PD Benefit Type: |  |  |  |
| 3. Segment ID: | 6. SNP: |  | 9. Enrollee Type: | 11. ESRD-SNP: | N | 14. SNP Type: | N/A |  |  |

## il. Spending in the Coverage Gap

Population Exceeding $\$ 4,660$ with Std Coverage
Amounts Allocated between $\$ 4,660$ and Catastrophic

1. Retail Generic

Retail Generic
2. Retail Preferred Brand
3. Retail Non-Preferred Brand
3. Retail Non-Preferred Brand

Retail Specialty Generic
5. Retail Specialty Brand
6. Mail Order Generic
7. Mail Order Preferred Brand
8. Mail Order Non-Preferred Brand
8. Mail Order Non-Preferred Brand
9. Mail Order Specialty Generic
0. Mail Order Specialty Brand
11. Total

Low Income Population Amounts Allocated between $\$ 4,660$ and Catastrophic
12. Retail Generic
13. Retail Preferred Brand
14. Retail Non-Preferred Brand
15. Retail Specialty Generic
6. Retail Specialty Brand
7. Mail Order Generic
18. Mail Order Preferred Brand
19. Mail Order Non-Preferred Brand
20. Mail Order Specialty Generic
21. Mail Order Specialty Brand
22. Total

Non-Low Income Population Amounts Allocated between $\$ 4,660$ and Catastrophic
23. Retail Generic
23. Retail Generic
. Retail Preferred Brand
. Retail Non-Preferred Brand
26. Retail Specialty Generi
27. Retail Specialty Brand
29. Mail Order Preferred Brand
30. Mail Order Non-Preferred Brand
31. Mail Order Specialty Generic
32. Mail Order Specialty Brand
33. Total

Non-LI Generics in Gap PMPM
I. General Information

| 1. Contract Number: | 4. Contract Yr: 2024 | 7. Plan Name: | 10. VBID-D: | N | 12. PD Region: |  | 15. PMM: |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2. Plan ID: | 5. Org. Name: | 8. Plan Type: |  |  | 13. PD Benefit Type: |  |  |
| 3. Segment ID: | 6. SNP: | 9. Enrollee Type: | 11. ESRD-SNP: | N | 14. SNP Type: | N/A |  |

## II. 2024 Defined Standard Benefit Parameters

| 1. Deductible | $\$ 505$ |
| :--- | ---: |
| 2. Initial Coverage Limit | $\$ 4,660$ |
| 3. | $\$ 7,400$ |

III. Summary of Key Bid Elements

| 1. Standardized Part D Bid <br> 2. National Average Monthly Bid Amount | \$0.00 |
| :---: | :---: |
|  |  |
| 3. Base Beneficiary Premium |  |
| Basic Part D Premium (prior to A/B rebate allocation) |  |
| 4. Unrounded | \$0.00 |
| 5. Rounded | \$0.00 |
| Supplemental Part D Premium (prior to $A / B$ rebate allocation) |  |
| 6. Unrounded | \$0.00 |
| 7. Rounded | \$0.00 |
| 8. Prospective federal reinsurance (non-standardized) | \$0.00 |
| 9. Prospective low-income cost sharing subsidy (non-standardized) | \$0.00 |
| 10. Target amount adjustment (allowed costs as a ratio of bid) | 1.0000 |
| 11. Prospective brand discount amount | \$0.00 |
| Rounding Rule |  |
| 12. Round Part D premiums to nearest | \$0.10 |



## IV. Part D Bid Pricing Tool Contacts

## Plan Bid Contact

Name
Phone
Email
Part D Certifying Actuary
Name and Credentials
Phone
Email
Part D Additional BPT Actuarial Contac
Name
Phone
Email
Date Prepared

